Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy

JAMA Ophthalmology

Volumn 132, Issue 1, 2014, Pages 32-37

  Schoenberger, Scott D ^a   Kim, Stephen J ^a   Shah, Rohan ^a   Sheng, Jinsong ^a   Cherney, Edward ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; EOTAXIN; EYE DROPS; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KETOROLAC TROMETAMOL; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; ARTICLE; CILIARY DISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DRUG USE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERVENTION STUDY; MIDDLE AGED; PHAKIC INTRAOCULAR LENS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; UNIVERSITY HOSPITAL; VITRECTOMY;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AQUEOUS HUMOR; DIABETIC RETINOPATHY; DINOPROSTONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-8; KETOROLAC TROMETHAMINE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PLATELET-DERIVED GROWTH FACTOR; PROSPECTIVE STUDIES; VITRECTOMY; VITREOUS BODY;

EID: 84892756877     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.6203     Document Type: Article

References (36)

1. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102(4):647-661.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
3. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):65-84.
4. 2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci. 2012;53(9):5906-5911.
5. Lange CA, Stavrakas P, Luhmann UF, et al. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. Am J Ophthalmol. 2011;152(3):406-412, e3.
6. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012;37(5):416-420.
7. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108-133.
8. Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. Clin Ophthalmol. 2011;5:751-758.
9. 2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci. 1998;39(3):581-591. (Pubitemid 28110692)
10. 4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci. 2009;50(11):5479-5486.
11. Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res. 1999;18(2):79-82. (Pubitemid 29137563)
12. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56(2):373-379.
13. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 2002;16(3):438-440.
14. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003;458(3):283-289. (Pubitemid 36009467)
15. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes. 1989;38(4):491-498.
16. Hattori Y, Hashizume K, Nakajima K, Nishimura Y, Naka M, Miyanaga K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Curr Med Res Opin. 2007;23(8):1913-1917. (Pubitemid 47300390)
17. Chew EY, Kim J, Coleman HR, et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina. 2010;30(3):459-467.
18. Kim SJ, Doherty TJ, Cherney EF. Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study. Arch Ophthalmol. 2012;130(4): 456-460.
19. Attar M, Schiffman R, Borbridge L, Farnes Q, Welty D. Ocular pharmacokinetics of 0.45% ketorolac tromethamine. Clin Ophthalmol. 2010;4:1403-1408.
20. Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013;2013:281981. doi:10.1155/2013/281981.
21. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12): 1450-1452. (Pubitemid 39561611)
22. 2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol. 2001;61(9):1153-1160. (Pubitemid 32285482)
23. 2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47(3):1149-1160. (Pubitemid 46768351)
24. Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32(10):2150- 2157.
25. Schoenberger SD, Kim SJ, Sheng J, Calcutt MW. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol. In press.
26. Kotyza J. Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: its diagnostic and prognostic values. A review. Int J Biol Markers. 2012;27(3):169-178.
27. Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30(9):1412-1419.
28. 2 induces interleukin-8 gene transcription by activating C/EBP homologous protein in human T lymphocytes. J Biol Chem. 2005;280(15):14433-14442. (Pubitemid 40562783)
29. Elner VM, Burnstine MA, Strieter RM, Kunkel SL, Elner SG. Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: immunochemical and in-situ hybridization analyses. Exp Eye Res. 1997;65(6):781-789. (Pubitemid 28053603)
30. Jacobi J, Kristal B, Chezar J, Shaul SM, Sela S. Exogenous superoxide mediates pro-oxidative, proinflammatory, and procoagulatory changes in primary endothelial cell cultures. Free Radic Biol Med. 2005;39(9):1238-1248. (Pubitemid 41407716)
31. Ghasemi H, Ghazanfari T, Yaraee R, Faghihzadeh S, Hassan ZM. Roles of IL-8 in ocular inflammations: a review. Ocul Immunol Inflamm. 2011;19(6): 401-412.
32. Mori K, Gehlbach P, Ando A, et al. Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci. 2002;43(6):2001-2006. (Pubitemid 34587053)
33. Cox OT, Simpson DA, Stitt AW, Gardiner TA. Sources of PDGF expression in murine retina and the effect of short-term diabetes. Mol Vis. 2003;9:665-672. (Pubitemid 38097632)
34. Campochiaro PA, Hackett SF, Vinores SA, et al. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci. 1994;107(pt 9):2459-2469. (Pubitemid 24292494)
35. Praidou A, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis D, Dimitrakos S. Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmol. 2011;89:248-254.
36. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152(4):686-694.